Chaudhari, Umesh
Sanofi (United States)
3 papers on CoChatORCID 0000-0002-7743-4371
Most cited papers
- Verified
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine
Lipoproteins and Cardiovascular HealthLipid metabolism and disorders
Cited by 2,296
- Verified
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
Kereiakes, D. J., Robinson, J. G., Cannon, C. P., Lorenzato, C., Pordy, R., Chaudhari, U., & Colhoun, H. M. (2015) · American Heart Journal
Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism
Cited by 349
- Verified · note
Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab
Robinson, J. G., Rosenson, R. S., Farnier, M., Chaudhari, U., Sasiela, W. J., Merlet, L., Miller, K., & Kastelein, J. J. P. (2017) · Journal of the American College of Cardiology
Lipoproteins and Cardiovascular HealthAntiplatelet Therapy and Cardiovascular Diseases
Cited by 197
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free